Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 9, 2025, Nancy J. Hutson, Ph.D. notified BioCryst Pharmaceuticals, Inc. (the "Company") of her intention to retire from the Board of Directors of the Company (the "Board"), effective as of the earlier of (i) the closing date of the previously announced proposed acquisition of Astria Therapeutics, Inc. and (ii) the date of the Company's 2026 annual meeting of stockholders (the earlier of such dates, the "Retirement Date"). Until the Retirement Date, Dr. Hutson is serving as Chair of the Board and the Compensation Committee of the Board, as well as a member of the Corporate Governance and Nominating Committee and the Science Committee of the Board. Dr. Hutson cited no disagreement with the Board or management relating to the Company, its operations, policies, or practices. The Company is grateful to Dr. Hutson for her fourteen years of service and appreciates her many contributions to the Company.

In connection with Dr. Hutson's notice of retirement, on December 9, 2025, the Board elected Vincent J. Milano as the next Chair of the Board, effective as of the Retirement Date.